Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients

Memo Therapeutics AG announced that the U.S. Food and Drug Administration has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus infection commonly seen in renal transplant patients.